RxDoctor Payments Data

Paul Kocsis, MD

Psychiatry · Lillington, NCNPI 1821041880

Payments from drug & device makers

$578in general payments, 2019–2025

Across 29 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$182
  • E.r. Squibb & Sons, L.L.C.$140
  • Otsuka America Pharmaceutical, Inc.$96
  • Johnson & Johnson$62
  • Neurocrine Biosciences, Inc.$38
  • Indivior Inc.$33
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$578 in reported general payments places this provider in the 65th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$20,264
Medicare patients
60
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole94$265,135
IngrezzaValbenazine Tosylate33$255,448
Invega SustennaPaliperidone Palmitate67$205,374
AristadaAripiprazole Lauroxil18$61,388
Clozapine65$8,820
Divalproex Sodium ErDivalproex Sodium85$5,802
Olanzapine232$5,254
Aripiprazole95$4,287
Risperidone132$2,464
Quetiapine Fumarate128$2,449
Lurasidone Hcl61$2,315
Topiramate39$2,097
Risperidone OdtRisperidone13$1,917
Divalproex Sodium78$1,748
Trazodone Hcl178$1,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$96$265,13594 claims
Neurocrine Biosciences, Inc.Ingrezza$38$255,44833 claims
Johnson & JohnsonInvega Sustenna$62$205,37467 claims
Alkermes, Inc.Aristada$182$61,38818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Lillington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →